GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group A/S (OCSE:PEG) » Definitions » Gross Profit

Pharma Equity Group A/S (OCSE:PEG) Gross Profit : kr0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Pharma Equity Group A/S Gross Profit?

Pharma Equity Group A/S's gross profit for the three months ended in Mar. 2024 was kr0.00 Mil. Pharma Equity Group A/S's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was kr0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Pharma Equity Group A/S's gross profit for the three months ended in Mar. 2024 was kr0.00 Mil. Pharma Equity Group A/S's Revenue for the three months ended in Mar. 2024 was kr0.00 Mil. Therefore, Pharma Equity Group A/S's Gross Margin % for the quarter that ended in Mar. 2024 was N/A%.

Pharma Equity Group A/S had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Pharma Equity Group A/S Gross Profit Historical Data

The historical data trend for Pharma Equity Group A/S's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group A/S Gross Profit Chart

Pharma Equity Group A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pharma Equity Group A/S Quarterly Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pharma Equity Group A/S's Gross Profit

For the Biotechnology subindustry, Pharma Equity Group A/S's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Equity Group A/S's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group A/S's Gross Profit distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group A/S's Gross Profit falls into.



Pharma Equity Group A/S Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Pharma Equity Group A/S's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Pharma Equity Group A/S's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Pharma Equity Group A/S's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Pharma Equity Group A/S  (OCSE:PEG) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Pharma Equity Group A/S had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Pharma Equity Group A/S Gross Profit Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group A/S's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Equity Group A/S (OCSE:PEG) Business Description

Traded in Other Exchanges
N/A
Address
Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970
Pharma Equity Group A/S is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develops technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement.